Leukemia is a malignant tumor of the hematopoietic systems. It has a poor prognosis due to a range of complicated features[@b1]. Based on the speed of onset and cytogenetic analysis, leukemia was divided into four main types[@b2]: acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Although leukemogenesis studies have been conducted for many years, the mechanisms underlying the development of this hematologic malignancy remain unclear. Multiple risk factors are thought to be implicated in leukemia, and genetic factors, such as constitutional genetic variation in components of DNA damage response pathways, have become the focus of research[@b3][@b4].

The TP53 tumor suppressor gene, which is located on chromosome 17p13, plays a pivotal role in the maintenance of genomic stability through encoding of the TP53 protein. The TP53 protein functions by regulating cell cycle arrest, DNA repair, apoptosis, and gene transcription to mediate cellular responses to DNA damage[@b5]. Frequent mutations and differential expression of TP53 in various cancers highlight the significance role of p53 in carcinogenesis and tumor progression[@b6][@b7]. A functional single-nucleotide polymorphism (SNP) at codon 72 of TP53 gene (rs1042522), encoding a transversion of G to C (Arg to Pro), has been demonstrated to be associated with interindividual differences of TP53 expression to malignant tumors, including leukemia[@b8]. In addition, it has been reported that the Arg72 variant induces apoptosis markedly better compared to the Pro72 variant[@b9]. Thus, this genetic polymorphism holds promise as a potential biomarker for leukemia.

To date, numerous studies have investigated the relationship between the *TP53* Arg72Pro polymorphism and predisposition to leukemia, but the impact of *TP53* Arg72Pro polymorphism on leukemia was still conflicting due to inconsistent findings in individual studies. It was necessary to quantitatively summarize the evidence using the gradually accumulated data. Therefore, the current meta-analysis of the 14 most recent and relevant case-control studies involving 2,506 cases and 4,386 controls was performed to provide a more precise estimate of the associations.

Results
=======

Characteristics of studies
--------------------------

A total of 14 case-control studies that examined the association of *TP53* Arg72Pro polymorphism with leukemia were included in the meta-analysis[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22]. As shown in the flowchart of the selection process of the included studies ([Fig. 1](#f1){ref-type="fig"}), one article was excluded because it was conducted on overlapping populations with another eligible study[@b23]; one article was excluded because the gene distribution of control group deviated from the HWE[@b24]; and one article involved two independent case-control studies that were considered separately, resulting in two studies[@b14]. Of the 14 studies, 8 were conducted in Asian populations, 5 in Caucasian populations, and one in a mixed population. There were 7 AML studies and 5 ALL studies, the remaining studies were CML, CLL, ATL and mixed types. There were 12 population-based studies and 2 hospital-based studies. The main characteristics of the selected studies and the genotype distribution of the *TP53* Arg72Pro polymorphism are summarized in [Table 1](#t1){ref-type="table"}.

Meta-analysis Results
---------------------

[Table 2](#t2){ref-type="table"} lists the main results of this meta-analysis. The results of pooling all studies showed that there was no statistically significant association between *TP53* Arg72Pro polymorphism and the risk of leukemia (C vs. G: OR = 1.09, 95% CI = 0.93--1.26; CC vs. GG: OR = 1.24, 95% CI = 0.91--1.69; CC + GC vs. GG: OR = 1.04, 95% CI = 0.85--1.28; CC vs. GC + GG: OR = 1.23, 95% CI = 0.96--1.57) (see [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). Likewise, no significant association was found in the stratified analysis by ethnicity. In the subgroup analysis by type of leukemia, we found no association between *TP53* Arg72Pro polymorphism and AML in all genetic models. However, we found a significant association between *TP53* Arg72Pro polymorphism and ALL under the recessive model (OR = 1.73, 95% CI = 1.07--2.81, P = 0.025) ([Fig. 2](#f2){ref-type="fig"}). When stratified restricting by control sources, negative results were observed in population-based controls and hospital-based controls.

Sensitivity analysis and Publication bias
-----------------------------------------

A sensitivity analysis was performed by sequentially omitting individual studies of *TP53* Arg72Pro polymorphism, and the corresponding pooled ORs were not materially changed (see [Supplementary Fig. S2](#S1){ref-type="supplementary-material"}). Begg's funnel plot and Egger's test were performed to access the publication bias in this meta-analysis. Funnel plot shapes did not reveal any obvious evidence of asymmetry, and the P value of the Egger's tests was greater than 0.05. The results suggested that publication bias was not evident in this meta-analysis (see [Supplementary Fig. S3](#S1){ref-type="supplementary-material"}).

Discussion
==========

The association between *TP53* genetic mutation and the susceptibility to tumor risk has been confirmed in several functional studies with genetically modified mice, and the results have indicated that mice lacking the inactivating mutation in one *TP53* allele developed fewer tumors than the mice harboring the mutation[@b25]. Moreover, the *TP53* Arg72Pro polymorphism is the most studied SNP that may be associated with tumor risk. Therefore, it is biologically plausible that this polymorphism has significant association with leukemia progression.

However, previous a meta-analysis has reported that *TP53* Arg72Pro polymorphism was not associated with leukemia risk, even in subgroup analyses by ethnicities and types of leukemia[@b26]. In the present meta-analysis, with 5 more studies and a larger number of subjects, we reached some meaningful conclusions. The overall summary results of our meta-analysis also suggested no statistically significant risk of *TP53* Arg72Pro polymorphism to leukemia, and no significant association was found in a subgroup analysis by ethnicity. When stratified by types of leukemia, we observed a significant association between *TP53* Arg72Pro polymorphism and ALL risk under the recessive model but not in the AML subjects. In the previous meta-analysis, which was limited by the number of studies, the authors only performed subgroup analyses on the association between *TP53* Arg72Pro polymorphism, the risk of AML (n = 5), and the risk of other types of leukemia (n = 4), and the results were consistent with ours. Thus, our study confirms the association between *TP53* Arg72Pro polymorphism and the risk of leukemia found in previous analysis. However, further studies with larger patient cohorts are needed to clarify this association.

ALL is more common in children, who comprise over 80% of all acute leukemia cases. Childhood ALL shows a consistent association with miscarriages[@b26], and the *TP53* Arg72Pro polymorphism has been implicated in implantation failure[@b27] and in recurrent miscarriages[@b28]. However, the association is controversial. Fraga *et al*. reported no association was observed between *TP53* Arg72Pro polymorphism and pregnancy loss risk, but the interaction of the TP53 Arg/Arg (rs1042522) and MDM2 TT (rs2279744) genotypes was shown to increase the risk to pregnancy loss[@b29]. This feature of childhood ALL makes it an interesting target for the study of TP53 pathway genes. *TP53* Arg72Pro polymorphism may be a modifier of risk for childhood ALL susceptibility and might interact with MDM2. The Arg72 variant is more efficient than the Pro72 variant at inducing apoptosis. The greater apoptotic potential of the Arg72 protein is caused by greater interaction of this protein with MDM2, which facilitates the nuclear export, and probably also the subsequent mitochondrial localization[@b31][@b32]. Consistent with their biological relationship, our current analysis provides evidence that the *TP53* Arg72Pro polymorphism is associated with an increased risk of developing ALL. To the best of our knowledge, this meta-analysis is the first to investigate the effect of *TP53* Arg72Pro polymorphism on ALL. Furthermore, due to a limited number of available published studies, further studies with larger sample sizes are needed to reach a more convincing conclusion.

In interpreting our results of this meta-analysis, some limitations must be addressed. First, our meta-analysis was based on unadjusted estimates. However, a more precise analysis might be conducted if individual data were available, such an analysis would have allowed us to adjust for other covariates, such as age, family history and environmental factors. Second, the *TP53* Arg72Pro polymorphism might influence susceptibility to leukemia with other factors, but we did not conduct relative research, such as the gene-gene and gene-environment interactions, because the data were insufficient. Third, we could not perform further subgroup stratification analysis by ages because of the limited number of published studies. Finally, publication bias is possible because no attempts were made to identify unpublished studies, although the results of our Begg's funnel plot and Egger's test revealed no evidence of publication bias in the allele model.

In conclusion, this meta-analysis did not find any evidence of an association between *TP53* Arg72Pro polymorphism and the risk of leukemia in the overall studies, without the influence of ethnic diversity. However, a statistically significant association was found there was a stronger power trend towards a risk between the *TP53* Arg72Pro polymorphism and ALL. Further studies with larger sample sizes and well-designed studies are required to investigate the associations between *TP53* Arg72Pro polymorphism and leukemia.

Materials and Methods
=====================

Identification of Eligible Studies
----------------------------------

A comprehensive literature search of studies published through December 2014 was performed using the PubMed, EMBASE, Web of Knowledge and the Chinese National Knowledge Infrastructure (CNKI) databases. Various combinations of the terms "TP53 or P53", "polymorphism or variant", and "leukemia or leucocythemia" were used to screen for potentially relevant studies. The search was conducted without language restrictions. Additional articles were located manually through the references of the related reports.

Inclusion and Exclusion Criteria
--------------------------------

The following inclusion criteria were applied: a) studies evaluating the association between *TP53* Arg72Pro polymorphism and the risk of leukemia, b) case-control or cohort studies, c) studies with a control genotype distribution in HWE, and d) studies with sufficient genotype data for calculating the odds ratio (OR) with 95% confidence intervals (95% CIs). If studies included overlapping subjects, only the study with a larger sample size was selected. Studies were excluded if one of the following existed: a) not a case-control study, b) no sufficient data were reported, and c) case reports or reviews.

Data Extraction
---------------

Two investigators (Dai and Sun) independently collected the data from each article using a standardized protocol. Disagreement was resolved by discussion with the other co-authors. The following information from the eligible studies was extracted: the first author's surname, publication year, country of origin, ethnicity, source of control, sample sizes of cases and controls, number of genotypes, *P*-value for Hardy-Weinberg equilibrium (HWE), and genotyping methods. The study design was categorized as a hospital-based study (controls from the hospitalized patients) or a population-based study (controls from the healthy population).

Quality score assessment
------------------------

The quality of the studies was independently assessed by the two reviewers (S.J., and J.S) according to the scale for quality assessment (see [Supplementary Table S1](#S1){ref-type="supplementary-material"}). These scores were based on both traditional epidemiological considerations and cancer genetic issues. Any disagreement was resolved by discussion between the two reviewers. Total scores ranged from 0 (worst) to 15 (best).

Statistical analysis
--------------------

All statistical analyses were performed using Stata software version 12.0 (Stata Corp., College Station, TX, USA), and all *P* values were two-sided. The Hardy-Weinberg equilibrium of controls for each study was tested using the χ^2^ test (significant at the 0.05 level). An OR with the corresponding 95% CI was used to assess the strength of the association between the *TP53* Arg72Pro polymorphism and leukemia susceptibility according to allelic contrast (C vs. G), homozygote comparisons (CC vs. GG), dominant models (CC + GC vs. GG) and recessive models (CC vs. GC + GG). The significance of the summary OR was determined with a Z-test, and a *p* value of less than 0.05 was considered to be statistically significant. Between-study heterogeneity was assessed by calculating the *Q*-statistic and then quantified using the *I*^*2*^ value. When the effects were assumed to be heterogeneous (P \< 0.05, I^2^ \> 50%), the random-effects model was used; otherwise, the fixed-effects model was more appropriate[@b33][@b34]. Sensitivity analysis was used to test the stability of pooled studies through sequential omission of individual studies. Potential publication bias was estimated with a Begg's funnel plot and corroborated with the Egger's test (P \< 0.05 was considered to indicate significant publication bias)[@b35][@b36]. Additionally, subgroup analyses of ethnicity, source of control and clinical types were performed.
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###### The characteristics of studies included in the meta-analysis.

  First author    Year     Country    Ethnicity   Source of control   Clinical types   Sample size Case/Control   Cases   Controls   HWE   Methods of genotyping   Quality scores                           
  -------------- ------- ----------- ----------- ------------------- ---------------- -------------------------- ------- ---------- ----- ----------------------- ---------------- ----- ------ ----------- ----
  Nakano          2000      Japan       Asian     Population based         AML                 200/188             82        93      25             59                   95         34    0.69     SSCP      13
  Bergamaschi     2004      Italy     Caucasian   Population based         CML                  96/174             49        37      10             106                  61          7    0.63   PCR-RFLP    11
  Takeuchi        2005      Japan       Asian      Hospital based          ATL                  87/89              33        38      16             32                   37         20    0.15   PCR-RFLP    10
  Kochethu        2006       UK       Caucasian   Population based         CLL                  203/97             119       62      22             44                   40         13    0.42   PCR-RFLP    11
  Ellis           2008a      USA      Caucasian   Population based         AML                 80/2224             42        35       3            1255                 838         131   0.57    Taqman     15
  Ellis           2008b      UK       Caucasian   Population based         AML                  91/798             53        31       7             459                 289         50    0.62   PCR-RFLP    14
  Phang           2008    Singapore     Asian     Population based         MIX                  44/160             13        25       6             56                   72         32    0.32   PCR-RFLP    11
  Xiong           2009      China       Asian      Hospital based          AML                 231/128             52       127      52             39                   64         25    0.89   PCR-RFLP    12
  Do              2009       US       Caucasian   Population based         ALL                 114/414             50        45      19             234                 154         26    0.92    Taqman     13
  Shi             2011      China       Asian     Population based         AML                 180/555             55        84      41             171                 289         95    0.15   MALDI-TOF   13
  Chauhan         2012      India       Asian     Population based         AML                 131/199             38        71      22             51                  112         36    0.06   PCR-RFLP    12
                                                                           ALL                  99/199             28        43      28             51                  112         36    0.06   PCR-RFLP    12
  Dunna           2012      India       Asian     Population based         ALL                 147/245             59        67      21             79                  123         43    0.68   PCR-RFLP    12
                                                                           AML                 141/245             64        44      33             79                  123         43    0.68   PCR-RFLP    12
  Chen            2013      China       Asian     Population based         ALL                 174/356             39        90      45             113                 183         60    0.33   PCR-RFLP    13
  Perim           2013     Brazil       Mixed     Population based         ALL                  54/58              24        23       7             37                   19          2    0.82   PCR-RFLP    10

*HWE*, Hardy-Weinberg equilibrium; *PCR*, polymerase chain reaction; *RFLP*, restriction fragment length polymorphism; *SSCP*, Single-Strand Conformation Polymorphism.

ALL, Acute lymphoblastic leukemia; AML, Acute myeloid leukemia; CLL, Chronic lymphocytic Leukemia; CML, Chronic myeloid leukemia; ATL, Adult T-cell leukemia.

###### Meta-analysis of the association between *TP53* Arg72Pro polymorphism and leukemia.

  Subgroup                               NO.       C vs. G                    CC vs. GG                        CC + GC vs. GG              CC vs. GC + GG                                                                                                                                                                                                                               
  ------------------------------------- ----- ------------------ ----------------------------------- ----------------------------------- ------------------- ----------------------------------- ----------------------------------- ------------------ ----------------------------------- ----------------------------------- ------------------- ----------------------------------- -----------------------------------
  Overall                                14    1.09(0.93--1.26)                 0.000                               0.272                 1.24(0.91--1.69)                  0.001                               0.203                 1.04(0.85--1.28)                 0.001                               0.530                 1.23(0.96--1.57)                  0.014                               0.106
  Ethnicity                                                                                                                                                                                                                                                                                                                                                                             
   Asian                                  8    1.02(0.86--1.20)                 0.012                               0.847                 1.07(0.77--1.49)                  0.024                               0.678                 0.98(0.76--1.27)                 0.011                               0.894                 1.16(0.96--1.38)    0.130[\*](#t2-fn1){ref-type="fn"}   0.120[\*](#t2-fn1){ref-type="fn"}
   Caucasian                              5    1.15(0.83--1.59)                 0.002                               0.415                 1.44(0.68--3.04)                  0.005                               0.337                 1.11(0.78--1.59)                 0.018                               0.552                 1.44(0.76--2.72)                  0.022                               0.263
   Mixed                                  1    2.11(1.15--3.86)                  --                                 0.016                 5.40(1.03--28.19)                  --                                 0.046                 2.20(1.03--4.70)                  --                                 0.041                 4.17(0.83--21.04)                  --                                 0.084
  Source of control                                                                                                                                                                                                                                                                                                                                                                     
   Population-based                      13    0.88(0.74--1.04)                 0.000                               0.127                 0.78(0.55--1.10)                  0.001                               0.158                 0.74(0.56--0.98)                 0.005                               0.038                 0.93(0.75--1.16)                  0.004                               0.529
   Hospital-based                         2    0.90(0.71--1.16)   0.197[\*](#t2-fn1){ref-type="fn"}                 0.423                 0.83(0.51--1.37)    0.185[\*](#t2-fn1){ref-type="fn"}                 0.469                 0.97(0.63--1.49)   0.353[\*](#t2-fn1){ref-type="fn"}                 0.885                 0.81(0.55--1.18)    0.214[\*](#t2-fn1){ref-type="fn"}                 0.267
  Clinical types                                                                                                                                                                                                                                                                                                                                                                        
   AML                                    7    0.98(0.88--1.10)   0.179[\*](#t2-fn1){ref-type="fn"}   0.730[\*](#t2-fn1){ref-type="fn"}   1.00(0.79--1.27)    0.208[\*](#t2-fn1){ref-type="fn"}   0.986[\*](#t2-fn1){ref-type="fn"}   0.91(0.72--1.16)                 0.048                               0.448                 1.11(0.89--1.37)    0.277[\*](#t2-fn1){ref-type="fn"}   0.351[\*](#t2-fn1){ref-type="fn"}
   ALL                                    5    1.33(0.97--1.82)                 0.002                               0.078                 1.83(0.95--3.50)                  0.003                               0.069                 1.26(0.84--1.90)                 0.008                               0.266                 1.73(1.07--2.81)                  0.022                             **0.025**
   Others[\#](#t2-fn2){ref-type="fn"}     4    0.97(0.68--1.39)                 0.035                               0.882                 0.95(0.61--1.48)    0.087[\*](#t2-fn1){ref-type="fn"}   0.827[\*](#t2-fn1){ref-type="fn"}   0.97(0.73--1.28)   0.056[\*](#t2-fn1){ref-type="fn"}   0.823[\*](#t2-fn1){ref-type="fn"}   0.93(0.62--1.40)                  0.129                 0.722[\*](#t2-fn1){ref-type="fn"}

*OR* odds ratio; 95% *CI*, 95% confidence interval; *P*~*OR*~, pool *P* value; *P*~*h*~, *P* value of heterogeneity test; NA, data not available.

^\*^Estimates for fixed-effects model; otherwise, random-effects model was used.

^\#^Others include chronic lymphocytic leukemia, chronic myeloid leukemia, adult T-cell leukemia, and mixed types.
